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Abstract
Introduction: Metformin associated lactic acidosis (MALA) may complicate metformin therapy, particularly if
metformin accumulates due to renal dysfunction. Profound lactic acidosis (LA) generally predicts poor outcome.
We aimed to determine if MALA differs in outcome from LA of other origin (LAOO).
Methods: We conducted a retrospective analysis of all patients admitted with LA to our medical ICU of a tertiary
referral center during a 5-year period. MALA patients and LAOO patients were compared with respect to
parameters of acid-base balance, serum creatinine, hospital outcome, Simplified Acute Physiology Score II (SAPS II)
and Sequential Organ Failure Assessment (SOFA) score, using Pearson’s Chi-square or the Mann-Whitney U-test.
Results: Of 197 patients admitted with LA, 10 had been diagnosed with MALA. With MALA, median arterial blood
pH was significantly lower (6.78 [range 6.5 to 6.94]) and serum lactate significantly higher (18.7 ± 5.3 mmol/L) than
with LAOO (pH 7.20 [range 6.46 to 7.35], mean serum lactate 11.2 ± 6.1 mmol/L). Overall mortality, however, was
comparable (MALA 50%, LAOO 74%). Furthermore, survival of patients with arterial blood pH < 7.00 (N = 41) was
significantly better (50% vs. 0%) if MALA (N = 10) was the underlying condition compared to LAOO (N = 31).
Conclusions: Compared to similarly severe lactic acidosis of other origin, the prognosis of MALA is significantly
better. MALA should be considered in metformin-treated patients presenting with lactic acidosis.
Introduction
Metformin is recommended as the treatment of choice
in patients with type 2 diabetes mellitus because it
decreases cardiovascular morbidity and mortality [1,2].
Nevertheless, metformin-associated lactic acidosis
(MALA) is a rare but potentially life-threatening compli-
cation with a mortality rate of 30% to 50% [3,4]. The
biochemical mechanism of MALA is still not fully
understood. Presumably, accumulated metformin sup-
presses biological oxidation and the enzymes of the
citric acid cycle [3,5-7]. Moreover, recent studies have
reported that metformin action may be mediated by the
regulation of gene expression [8-10]. The pathogenesis
of MALA is controversial. MALA is assumed to be trig-
gered by an acute primary tissue hypoxia as in septic
shock or cardiovascular failure in most cases [1,3,11,12].
Some authors dispute whether metformin may contri-
bute to lactic acidosis (LA) at all [12,13]. However, cases
of MALA solely following drug accumulation have been
reported [5,14-16]. Furthermore, data from a US poison
center give some evidence that a large single ingestion
can lead to LA [17]. Remarkably, severe MALA may
have an unexpectedly favorable outcome [4,14,15].
Therefore, the aim of this study was to compare the
outcomes of MALA and LA of other origin (LAOO).
Materials and methods
This retrospective analysis was approved by the institu-
tional ethics committee at Ernst Moritz Arndt University
of Greifswald. The necessity of patient consent was
waived. All patients admitted to the medical intensive
care unit of our tertiary referral center during a 5-year
period (2004 to 2008) were screened for LA (that is, lac-
tate of greater than 5 mmol/L and pH of not more than
7.35 [11]) on admission by using the laboratory database.
Clinical characteristics, admission laboratory results,
metformin plasma levels, and hospital survival of all LA
patients were extracted from patient files. To compare
severity of disease, Simplified Acute Physiology Score II
(SAPS II) [18,19] and Sequential Organ Failure
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Assessment (SOFA) score [20,21] were extracted from
the ward database. According to discharge diagnoses,
patients were categorized under the following entities of
LA: MALA, post-cardiopulmonary resuscitation, septic
shock, cardiogenic shock, acute mesenteric ischemia,
hemorrhagic shock, or other. The diagnosis of MALA
was confirmed retrospectively by critical review of
patient charts, which included data on medical history,
clinical presentation, highly elevated plasma levels of
metformin, and absence of other common causes of LA.
None of the patients had evidence of hepatic failure. All
MALA patients had an electrocardiogram and a bedside
echocardiogram to rule out myocardial infarction and
relevant cardiac dysfunction. None had evidence of a
septic focus in chest x-ray, abdominal or thoracic ultra-
sound, blood cultures, urinary dipstick (if not anuric), or
computed tomography (if indicated). MALA patients
were compared with all LAOO patients and with the
severely acidotic subgroup (pH < 7.0) of LAOO patients
with respect to parameters of acid-base balance, serum
creatinine, SAPS II, and hospital outcome by using the
Pearson chi-square test or the Mann-Whitney U test.
Results
During the study period, 197 patients were admitted with
LA. MALA was diagnosed in 10 patients, none had deliber-
ately overdosed (daily metformin dose of 1,900 ± 356 mg),
but all had severe renal failure (median admission serum
creatinine of 776 μmol/L, range of 347 to 1,502) that had
not been noticed before. In 6 patients, previous diarrhea or
vomiting or both were reported; in the other 4, no cause
for acute renal failure could be identified, but 3 of them
had pre-existing chronic renal insufficiency. Metformin
plasma levels were highly toxic in all MALA patients (med-
ian of 55 mg/L, range of 31 to 85, therapeutic range of 0.2
to 1.3). All MALA patients were in circulatory shock and
were treated with vasopressors. Nevertheless, in 8 of them,
circulatory failure deteriorated up to cardiocirculatory
arrest, which was reversible with cardiopulmonary resusci-
tation. All MALA patients were mechanically ventilated
and immediately treated with continuous veno-venous
hemodialysis or hemofiltration. In MALA, LA and renal
dysfunction were significantly more severe, other organ
dysfunctions were similar, but mortality was not signifi-
cantly higher compared with all LAOO patients and with
each of the causal entities of LAOO (Table 1).
All MALA patients and 31 of the LAOO patients had
very severe acidosis (pH < 7.0). In this subgroup, acid-
base imbalance in MALA was still slightly more profound
than in LAOO, severity of disease and non-renal organ
dysfunction (SAPS II and SOFA score) were comparable,
but outcome was significantly better (50% survivors in
MALA versus 0% in LAOO) (Table 2).
There was no difference within the MALA group
between survivors and non-survivors in regard to serum
metformin level, the degree of LA, or organ dysfunction




























Age, years 67 ± 13 66 ± 9 67 ± 13 65 ± 13 68 ± 12 73 ± 11 72 ± 9 64 ± 15 56 ± 14
Male gender 121 (61%) 4 (40%) 117 (63%) 45 (62%) 24 (57%) 26 (67%) 6 (75%) 7 (54%) 9 (69%)
SAPS II 74 ± 20 88 ± 23 73 ± 19a 81 ± 16 71 ± 19a 75 ± 18 73 ± 25 54 ± 15b 54 ± 14b
SOFA score 12.5 ± 3.6 14.3 ± 1.4 12.4 ± 3.7 12.9 ± 2.9 12.1 ± 4.5 11.8 ± 2.8b 14.4 ± 4.4 13.4 ± 4.6 9.6 ± 4.2b
Respiratory 2.5 ± 1.0 2.7 ± 0.9 2.5 ± 1.0 2.7 ± 0.9 2.1 ± 1.3 2.4 ± 0.6 2.6 ± 1.1 2.3 ± 1.5 2.2 ± 1.4
Renal 2.4 ± 1.2 4.0 ± 0.0 2.3 ± 1.2b 2.1 ± 1.2b 2.5 ± 1.2b 2.5 ± 1.1b 2.8 ± 0.8a 2.1 ± 1.5b 1.9 ± 1.3b
Hepatic 0.7 ± 1.0 0.3 ± 0.7 0.7 ± 1.0 0.3 ± 0.6 1.3 ± 1.2a 0.6 ± 0.8 0.6 ± 0.9 1.8 ± 1.7 0.9 ± 0.9
Cardiovascular 3.3 ± 1.4 4.0 ± 0.0 3.3 ± 1.5 3.5 ± 1.3 3.2 ± 1.5 3.4 ± 1.5 4.0 ± 0.0 2.9 ± 1.8 2.1 ± 2.0a
Hematologic 0.9 ± 1.2 0.5 ± 0.8 0.9 ± 1.2 0.6 ± 0.9 1.3 ± 1.4 0.3 ± 0.7 2.2 ± 1.6 2.6 ± 1.1 0.9 ± 1.2
Neurologic 2.7 ± 1.4 2.8 ± 1.5 2.7 ± 1.4 3.7 ± 0.6a 1.7 ± 1.3a 2.8 ± 1.2 2.2 ± 1.3 1.8 ± 1.4b 1.6 ± 1.2
Lactate, mmol/L 11.6 ± 6.2 18.7 ± 5.3 11.2 ± 6.1b 12.8 ± 6.1b 8.7 ± 4.5b 10.9 ± 5.2b 8.6 ± 3.3b 13.5 ± 9.5b 10.8 ± 7.1b




7.07 ± 0.19b 7.23 ± 0.09b 7.18 ± 0.14b 7.27 ± 0.04b 7.26 ± 0.07b 7.14 ± 0.18b
Bicarbonate,
mmol/L
14.6 ± 5.9 4.4 ± 2.4 15.2 ± 5.6b 14.5 ± 5.6b 16.6 ± 5.8b 14.9 ± 4.0b 16.2 ± 1.8b 15.8 ± 5.7b 14.1 ± 8.8b
Creatinine, μmol/L 307 ± 265 796 ± 324 227 ± 141b 169 ± 128b 318 ± 181b 182 ± 48b 299 ± 125a 303 ± 122a 214 ± 57b
Survival 52 (26%) 5 (50%) 48 (26%) 19 (26%) 9 (21%) 9 (23%) 0 5 (38%) 6 (46%)
Values are presented as mean ± standard deviation or as number (percentage). Comparison with metformin-associated lactic acidosis (MALA): aP < 0.05, bP <
0.01. Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment (SOFA) score were measured on admission. Other causes of lactic
acidosis were respiratory exhaustion (3), alcoholic lactic acidosis (3), acute liver failure (2), status epilepticus (2), anaphylactic shock, hypovolemic shock, and
disseminated intravascular coagulation in acute myeloid leukemia. LAOO, lactic acidosis of other origin.
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(Table 3). MALA patients who did not survive died
from refractory circulatory failure after a median of
27 hours (range of 3 to 41 hours) from intensive care
unit admission.
Discussion
In 10 out of 197 patients in our study, LA on admission
was found to be associated with metformin accumula-
tion. MALA patients had the most severe acid-base
imbalance but did not have a worse outcome. Mortality
rates in our study are in accordance with those pub-
lished by other authors. For MALA, a mortality of 30%
to 50% has been reported [3,4,22]; for LA in general, a
mortality of up to 83% has been reported [23,24].
Mortality is generally correlated with lactate levels
[24,25]. For MALA, data are less clear. After a retrospec-
tive analysis in 1999, Lalau and Race [25,26] reasoned
that neither lactate nor metformin levels were of prog-
nostic value in MALA since, in their study, the lactate
and metformin levels of survivors were, respectively,
similar to and higher than those of patients who died.
The authors suppose that the underlying condition, and
not metformin accumulation, determined outcome. In
contrast, Dell’Aglio and colleagues [27] reported a corre-
lation between pH nadir, metformin level, and outcome.
Recently, observations in two series of MALA were
published [4,22]. Peters and colleagues [22] reported
30 patients who were generally less sick than ours (less
Table 3 Comparison of survived versus deceased patients with metformin-associated lactic acidosis
All patients with MALA (n = 10) Survived (n = 5) Deceased (n = 5)
Age, years 66 ± 9 64 ± 5 69 ± 11
Male gender 4 (40%) 3 (60%) 1 (20%)
SAPS II 88 ± 23 73 ± 25 103 ± 7
SOFA score 14.3 ± 1.4 13.8 ± 1.5 14.8 ± 1.3
Respiratory 2.7 ± 0.9 2.4 ± 1.1 3.0 ± 0.7
Renal 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Hepatic 0.3 ± 0.7 0.4 ± 0.9 0.2 ± 0.4
Cardiovascular 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Hematologic 0.5 ± 0.8 0.4 ± 0.9 0.6 ± 0.9
Neurologic 2.8 ± 1.5 2.6 ± 1.3 3.0 ± 1.7
Lactate, mmol/L 18.7 ± 5.3 17.7 ± 5.3 19.8 ± 5.7
pH 6.75 ± 0.13 6.72 ± 0.17 6.77 ± 0.07
Prothrombin activity, % 69.1 ± 27.7a 78.0 ± 24.6 58.0 ± 30.7a
Serum metformin, mg/L 55 ± 13 52 ± 7 58 ± 19
Values other than ‘Male gender’, which is presented as number (percentage), are presented as mean ± standard deviation. aOne patient was omitted with 11%
prothrombin activity due to cumarin therapy. MALA, metformin-associated lactic acidosis; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ
Failure Assessment.
Table 2 Comparison of metformin-associated lactic acidosis and very severe lactic acidosis of other origin (pH < 7.0)
All patients with pH < 7.0 (n = 41) MALA (n = 10) LAOO (n = 31)
Age, years 64 ± 13 66 ± 9 64 ± 14
Male gender 19 (46%) 4 (40%) 15 (48%)
SAPS II 84 ± 18 88 ± 23 83 ± 16
SOFA score 14.0 ± 2.9 14.3 ± 1.4 13.8 ± 3.4
Respiratory 2.7 ± 1.0 2.7 ± 0.9 2.8 ± 1.0
Renal 3.0 ± 1.1 4.0 ± 0.0 2.6 ± 1.1a
Hepatic 0.5 ± 0.8 0.3 ± 0.7 0.6 ± 0.9
Cardiovascular 3.6 ± 1.2 4.0 ± 0.0 3.4 ± 1.4
Hematologic 0.8 ± 1.1 0.5 ± 0.8 0.9 ± 1.2
Neurologic 3.3 ± 1.2 2.8 ± 1.5 3.5 ± 1.1
Lactate, mmol/L 18.1 ± 6.5 18.7 ± 5.3 17.9 ± 6.9
pH 6.83 ± 0.12 6.75 ± 0.13 6.86 ± 0.11a
Bicarbonate, mmol/L 9.0 ± 4.8 4.4 ± 2.4 10.5 ± 4.5a
Creatinine, μmol/L 529 ± 392 796 ± 324 195 ± 91a
Survival 4 (10%) 5 (50%) 0 (0%)a
Values are presented as mean ± standard deviation or as number (percentage). Comparison with metformin-associated lactic acidosis (MALA): aP < 0.01. LAOO,
lactic acidosis of other origin; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.
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acidotic, less frequently in shock, lower SAPS II, and
less frequently ventilated) and in whom mortality was
30% compared with our 50%. Seidowsky and colleagues
[4] reported 42 patients, 29 of whom had incidental
metformin accumulation. In these 29 patients, severity
of acidosis (mean pH of 6.9) and mortality (48.3%) were
comparable to those of our MALA patients [4]. In both
series, decreased prothrombin activity on admission was
associated with mortality [4,22]. In our small number of
cases, we could not reproduce this association.
Compared with our LAOO subgroup with similarly
severe acid-base imbalance (pH < 7.0), the outcome of
MALA patients was significantly better. Lalau and Race
[28] reported decreased mortality for patients who had a
pH of less than 7 and who had been treated with met-
formin (81% versus 99%) and this is consistent with our
results.
We suppose that the different outcomes of MALA and
LAOO may have been because, unlike most cases of
LAOO, LA in MALA is not due primarily to shock or
ischemia and because our patients had no underlying
condition serious enough to cause severe LA in the
absence of metformin accumulation. Furthermore, it has
been hypothesized that metformin, possibly through its
beneficial effects on vasomotility, might even be protec-
tive in shock [26,29].
MALA may develop without an underlying disease or
may aggravate LAOO, or metformin may accumulate just
coincidentally with LA [3,12]. In any given patient, it will
be difficult to establish the causative role of metformin
accumulation in the development of LA [4]. Further-
more, the role of metformin in the development of LA is
controversial; some authors deny any causal involvement
[12,13] altogether, and others believe that metformin
actually induces LA in certain cases [30]. Clinical data in
general and our retrospective observation in particular
are not suitable to decide this issue definitely, but our
results and those of other authors point to the latter posi-
tion [4,5,14-17,22,27]. In our MALA patients, no other
cause for LA was identified, and highly elevated metfor-
min plasma levels were measured. In these patients, pre-
viously unnoticed deterioration of renal function
explained why metformin had accumulated despite hav-
ing been taken in usual doses. The much greater extent
of renal dysfunction in MALA compared with similarly
severe LAOO suggests that renal failure not only
complicated MALA but also indeed contributed to the
pathogenesis. Progressive renal impairment has been
recognized as a risk factor for MALA [14,15,30] and can-
not be held responsible for LA as a single condition in
the absence of metformin [31].
MALA may be more common in severely acidotic
patients: 24% of our patients with pH of less than 7
were diagnosed with MALA. Therefore, given the
unexpectedly favorable prognosis, it appears important
to consider MALA and look into the possibility of met-
formin therapy when a patient is admitted with very
severe LA. It may be safely assumed that, in such
severely ill patients, only prompt and rigorous therapy
allows this favorable prognosis [14]. Anecdotal evidence
suggests that high-volume renal replacement therapy
may be beneficial in severe MALA [5,32,33].
Limitations
Our study included a limited number of patients. The
incidence of MALA is low, and therefore recruitment of
patients is demanding. In this study, we included 10
patients seen in one institution during a 5-year period.
A second limitation is the retrospective design. A bias in
patient selection cannot be excluded. As metformin
levels were usually not determined in cases in which
alternative causes of LA had been identified, coincident
metformin accumulation may have been missed. To our
knowledge, though, this is the first direct comparison
between MALA and LAOO.
Conclusions
The outcome of very severe MALA (pH < 7) is much
better than might be expected from the comparison
with similarly severe LAOO. To ensure adequate ther-
apy, it appears important to consider an association
with metformin and look into the possibility of metfor-
min medication in all cases of very severe LA.
Key messages
• Given the same profound level of acidosis, prog-
nosis of metformin-associated lactic acidosis
(MALA) is significantly better than that of lactic
acidosis of other origin.
• It is important to consider MALA in any metfor-
min-treated patient and to start therapy promptly.
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